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Abstract 
 
Gremlin (Grem1) is a member of the DAN family of secreted bone morphogenetic protein (BMP) 
antagonists. Bone morphogenetic protein-7 (BMP-7) mediates protective effects during renal fibrosis-
associated with diabetes and other renal diseases. The pathogenic mechanism of Grem1 during DN has 
been suggested to be binding and inhibition of BMP-7. However, the precise interactions between 
Grem1, BMP-7 and other BMPs have not been accurately defined. Here we show the affinity of 
Grem1 for BMP-7 is lower than that of BMP-2 and BMP-4, using a combination of surface plasmon 
resonance and cell culture techniques. Using kidney proximal tubule cells and HEK-293 cell 
Smad1/5/8 phosphorylation and BMP-dependent gene expression as readout, Grem1 consistently 
demonstrated a higher affinity for BMP-2>4>7. Cell-associated Grem1 did not inhibit BMP-2 or 
BMP-4 mediated signalling, suggesting that Grem1-BMP-2 binding occurred in solution, preventing 
BMP receptor activation. These data suggest that Grem1 preferentially binds to BMP-2 and this may 
be the dominant complex in a disease situation where levels of Grem1 and BMPs are elevated. 
  
 
 
Summary Statement 
 
Gremlin1 has a distinct preference for which bone morphogenetic protein it binds to in kidney 
epithelial cells. Grem1-BMP-2 complexes are favoured over other BMPs, and this may play an 
important role in fibrotic kidney disease. 
 
 
 
Introduction 
 
Bone morphogenetic proteins (BMPs) are glycosylated extracellular matrix associated members of the 
transforming growth factor beta (TGF-β) super-family [1]. BMPs were originally identified for their 
ability to induce bone formation in vivo via osteoblast differentiation [2, 3]. BMPs have a key function 
in morphogenesis, general organogenesis, cartilage and limb formation, as well as cell proliferation, 
differentiation and apoptosis [1, 3-5]. BMPs have a critical role in kidney development as evidenced 
by data showing that BMP-7 null mice are postnatal lethal due to various developmental abnormalities 
including kidney agenesis [6, 7]. Whereas BMP-4 has been shown to contribute to renal fibrosis, 
conflicting evidence exists for the pro- or anti-fibrotic role of BMP-2 in this process [8-11]. BMP-7 is 
thought of as anti-fibrotic, and has been the focus of many groups who demonstrated its anti-fibrotic 
activity in models of diabetic nephropathy and other kidney fibrotic diseases [5, 12-17]. To date, 
however, efforts to translate these data into BMP-7-centred treatment of fibrosis have been rather slow 
to develop [18, 19] 
Canonical BMPs signalling involves the Smad pathway, where BMP dimers bind to type I and 
type II BMP receptors leading to the formation of a hexameric complex, triggering receptor 
phosphorylation. This leads to phosphorylation of R-Smads (Smad1/5/8) and complex formation with 
co-Smad4 which translocates to the nucleus to regulate BMP target gene expression [1, 2]. BMP target 
genes include inhibitor of differentiation (Id 1-3) genes and inhibitory Smad 6 [1, 2]. BMP signalling 
is regulated on multiple levels: intracellularly by inhibitory Smads (Smad 6, 7), miRNAs, methylation 
and extracellularly by pseudoreceptors such as BAMBI and BMP antagonists including Gremlin 
(Grem1), Nogginand twisted gastrulation 1 (Twsg 1) [1, 2, 20]. 
Grem1 is an 184 amino acid (25 kDa) cysteine knot superfamily protein that exists in both 
secreted and cell associated forms [21]. Grem1 exerts an inhibitory effect by directly binding to BMP 
dimers, preventing their interaction with BMP receptors, as well as blocking BMP secretion and 
increasing extracellular BMP endocytosis [1, 22, 23]. Typically, homozygous Grem1 deletion in mice 
leads to neonatal lethality due to development abnormalities including bilateral agenesis of the 
kidneys, lung defects and limb malformations [24, 25]. However, recently it has been shown that some 
grem1 null mice survive when generated on a mixed genetic background (C57BL/6/FVB, 27). Grem1 
null mice were smaller, with decreased weight  and a shortened femoral length [26]. The lack of 
kidney development in grem1-/- mice was rescued by deletion of one allele of BMP-4 [27]. 
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Conversely, deletion of both alleles of BMP-7 rescued the ureteric branching defect but not the 
nephrogenesis defect [28], highlighting the critical nature of the balance between Grem1 levels and 
individual BMPs during kidney development.Grem1 is induced in response to high glucose in human 
mesangial cells, human proximal tubule epithelial cells and podocytes [29-33]. Grem1 is implicated in 
fibrotic diseases including diabetic nephropathy [32, 33], chronic allograft nephropathy [34], immune 
glomerulonephritis [35] and human idiopathic pulmonary fibrosis [36]. Heterozygous grem1 deletion 
in mice protects against early DN-like changes in a streptozotocin (STZ) model of diabetes [32].  
Additionally, siRNA silencing of Grem1 has shown beneficial effects in an STZ mouse model through 
maintaining BMP-7 activity and reducing DN-like characteristics [37]. The increased level of Grem1 
in fibrotic kidney disease is thought to contribute to pathogenesis via inappropriate inhibition of BMP 
signalling.  
The aim of this study was to characterise Grem1 binding to BMP-7 and other BMPs. Our data 
suggest that Grem1 has a low affinity for BMP-7, and preferentially binds to BMP-2 using kidney 
epithelial cells as a model. Our results will help to refine our model of how Grem1 contributes to 
kidney fibrosis during diabetes and other diseases.  
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Experimental Procedures 
 
Detection of rhGrem1, BMP-2, BMP-4 and BMP-7 by Coomassie Violet staining and Western 
blot.  
For Coomassie Violet staining, recombinant human (rh) Grem1, BMP-2, BMP-4, BMP-6 and BMP-7 
(R&D Systems, Minneapolis, USA) samples were prepared at 0.5 µg and 1.0 µg via dilution with the 
appropriate vehicle (PBS (Grem1) or 4 mM HCl (BMPs)) and added to an equal volume of 2 x 
Laemmli buffer without supplemental reducing agent. Samples were separated without boiling on 10 
% (v/v) SDS-PAGE and stained with Coomassie Violet solution  
 
For Western blotting, recombinant human (rh) Grem1, BMP-2, BMP-4, BMP-6and BMP-7 samples 
were prepared at 100 ng and 500 ng via dilution with the appropriate vehicle (PBS (Grem1) or 4 mM 
HCl (BMPs)) and added to an equal volume of 2 x Laemmli buffer in the absence of reducing agent. 
Samples were separated without boiling on 10 % (v/v) SDS-PAGE and probed via Western blotting 
using antibodies reactive to Grem1, BMP-2, BMP-4 or BMP-7 (R&D Systems, Minneapolis, USA). 
 
Surface Plasmon Resonance (SPR) 
Recombinant human BMP-2, 4, 6, 7 (R&D Systems, Minneapolis, USA) were immobilised onto 
individual flow channels of Xantec SPR Sensorchip HLC 30m (XanTec bioanalytics GmbH, 
Germany) via an amine coupling procedure. The surface of the Xantec SPR Sensorchip HLC 30m was 
pre-equilibrated with borate elution buffer (30 μL; flow rate: 10 μL/min) (XanTec bioanalytics GmbH, 
Germany) before being activated with a 1:1 mixture of 0.4 M 1-ethyl-3-(3-
dimethylaminopropyl)carbodimide (EDC) and 0.1 M N-hydroxysuccinimide (NHS) (50μL; flow rate 
10μL/min) (GE Healthcare, Uppsala, Sweden). rhBMPs were reconstituted at 100 μg/ml in 10 mM 
sodium acetate buffer pH 5.5 (GE Healthcare, Uppsala, Sweden) and diluted 1:100 with the same 
buffer. Twenty μL rhBMPs were injected at a flow rate of 10 μL/min until a response of 
approximately 500 RU was obtained. Remaining reactive sites on the flow channels were deactivated 
with 1 M ethanolamine pH 8.5 (70 μL; flow rate: 10 μL/min). 
Recombinant hGrem1 was reconstituted at 200 μg/ml (10 M) in running buffer (2 x PBS-20 mM 
phosphate, 5.4 mM KCl, 274 nM NaCl and 0.05 % (v/v) Tween-20). Increasing concentrations of 
rhGrem1 were injected in the running buffer for 120 s (60 μL at a flow rate of 30 μL/min; dissociation 
time: 480 s. Regeneration injections were performed with 10 mM glycine HCl pH 1.5 after each 
rhGrem1 injection (20 μL, flow rate 30 μL/min). Sensorgrams were subjected to double referencing 
with subtraction of their respective control sensorgrams and blank injections. Experiments were 
performed on a Biacore 3000 instrument. 
 
Size exclusion chromatography 
Size exclusion chromatography (SEC) was performed at 20 °C with a Shimadzu high-performance 
liquid chromatography (HPLC) apparatus connected to Wyatt Dawn Heleos II light scattering and 
Optilab  rEX instruments (Wyatt Technology, CA). SEC was performed in 2 x PBS using a 15 mL 
analytical KW-803 SEC column (Shodex, Japan) that was housed inside a thermostatted column oven. 
Five µL protein samples were injected at protein concentrations of ~50 µM.  
 
Microscale thermophoresis 
Protein samples were labelled for microscale thermophoresis (MST) measurements using an amine 
reactive coupling reaction (specifically a NT-647 N-hydroxysuccinimide protein-labelling kit, 
NanoTemper Technologies, Germany).  Tween 20 was added to the 2 x PBS buffer to a final 
concentration of 0.05 % (v/v) to reduce protein adsorption to plasticware and the side-walls of the 
disposable glass capillaries used for MST measurements. One hundred nM labelled BMP-4 was 
titrated with unlabeled Grem1 using a series of 1:2 serial dilutions (up to a maximum concentration of 
1 µM Grem). Four µL of each sample was then aspirated into hydrophilic capillaries, and MST 
measurements performed at 22 °C using a Monolith NT.115 (NanoTemper Technologies, Germany).  
The light-emitting diode that excites labelled protein fluorescence was set to 30 %, and a heating laser 
power of 40 % was used to induce the temperature gradient that MST measurements employ.  Laser 
on and off times were set to 30 s and 5 s, respectively. 
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Cell culture 
Human kidney proximal tubule epithelial cells (HK-2) were cultured as previously described [33]. 
HEK293T cells were grown in DMEM media containing 10 % (v/v) foetal calf serum and 100 g/ml 
primocin (Invivogen, UK).  
 
Cell treatments-Western blotting 
For BMP stimulation of Smad1/5/8 phosphorylation, HK-2 and HEK293 cells were plated on 60 mm 
plates. At 70 % confluence, cells were washed with 1 x PBS and treated with HK-2 complete medium 
supplemented with vehicle (4 mM HCl) or increasing concentrations  of rhBMP-2, rhBMP-4 (0.5-10 
ng/ml) or rhBMP-7 (5-50 ng/ml) (R&D Systems, Minneapolis, USA) for 60 min. For rhGrem1 
inhibition experiments, HK-2 cells were treated with complete medium supplemented with vehicle (4 
mM HCl), 5 ng/ml rhBMP-2, 5 ng/ml rhBMP-4 or 20 ng/ml rhBMP-7 in the absence or presence of 
increasing concentrations of rhGrem1 (5-400 ng/ml) (R&D Systems, Minneapolis, USA) for 60 min. 
rhGrem1 and BMP proteins were co-incubated in complete medium at 37 oC for 15 min prior to 
adding to cells.To assess the effect of cell associated Grem1, HK-2 cells were pre-treated with HK-2 
complete medium supplemented with vehicle (PBS), 25 ng/ml Grem1 (for BMP-2) or 200 ng/ml 
Grem1 (for BMP-4) for 60 min. The medium was removed and replaced with fresh HK-2 complete 
medium supplemented with vehicle (4 mM HCl), 5 ng/ml BMP-2 or 5 ng/ml BMP-2 plus 25 ng/ml 
rhGrem1. A similar approach was employed for BMP-4, with 5 ng/ml BMP-4 and 200 ng/ml rhGrem1 
utilized.  
 
Construction of pcDNA3.1/myc-hisA-hGrem1 plasmid 
A DNA fragment containing the entire coding sequence for Grem1 was amplified by RT-PCR on 
cDNA from HK-2 cells using forward primer 5′-
GACAGTGAATTCATGAGCCGCACAGCCTACACG-3′ and reverse primer 3′-
GGATTTTCTAGAATCCAAATCGATGGATATGCA-5’ and RedTaq® DNA polymerase at an 
annealing temperature of 55 °C. The fragment was restriction digested using EcoR1 and Xba1 
(Fermentas, UK) to create sticky ends. The fragment was ligated using T4 DNA ligase (Life 
Technologies, UK) into pcDNA™3.1/myc-hisA (Invitrogen, UK) that was cut with EcoR1 and Xba1.  
The ligated product was used to transform competent XL-1 blue E.coli (Agilent Technologies) which 
were then plated onto LB-ampicillin plates. Positive colonies were identified by PCR, and 
pcDNA3.1/myc-hisA-hGrem1 plasmid was extracted from cells using Pure Yield™ Plasmid Maxiprep 
system (Promega, UK). All final plasmid DNA was validated by Sanger sequencing. 
 
Transfection and immunocytochemistry of HEK293 cells 
HEK293 cells were grown on glass coverslips were transfected with empty plasmid (pcDNA3.1) or 
plasmid containing full-length human Grem1 cDNA (pcDNA3.1-hGrem1) using LipofectamineTM 
2000 (Invitrogen UK). Forty eight hours post-transfection, cells were incubated in serum free DMEM 
for 4 h and treated with vehicle (4 mM HCl) or 5 ng/ml BMP-2 for 60 min. Cells were fixed in 4 % 
PFA, permeabilised with 0.1 % Triton-X, blocked in 1 % BSA and stained with -myc (9E10) and 
pSMAD1/5 (Cell Signalling) primary antibodies. Anti-mouse TRITC and anti-rabbit FITC secondary 
antibodies were used for detection, together with DAPI (blue) to visualise the nuclei.  
 
Conditioned medium from empty vector and pcDNA3.1-hGrem1 transfected cells of various dilutions 
was added to fresh, non-transfected HEK293 cells in the presence of 5 ng/ml rhBMP-2, 4 or 7 for 60 
min. Cells were lysed in supplemented RIPA buffer and Western blotting for phospho-Smad1/5/8 and 
β-actin was carried out exactly as described [38, 39]. Densitometry analysis was performed using 
Image J software (http://rsbweb.nih.gov/ij/) and pSmad1/5/8 band intensities were expressed as a ratio 
of β-actin loading control intensity for each sample. 
 
Real-time quantitative PCR 
For BMP stimulation and Grem1 inhibition of BMP gene responses, HK-2 cells were plated on 60 mm 
plates. At 70 % confluence, cells were washed with 1 x PBS and treated with HK-2 complete medium 
supplemented with vehicle (4 mM HCl), 10 ng/ml rhBMP-2, 10 ng/ml rhBMP-4, or 20 ng/ml rhBMP-
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7 in the absence or presence of increasing concentrations of rhGrem1 (25 – 400 ng/ml) for 2 h. 
Recombinant proteins were co-incubated in complete medium at 37 oC for 15 min prior to adding to 
the cells.  RNA was extracted using an RNeasy RNA extraction kit according to the manufacturers 
protocol (Qiagen). Total RNA (1 μg) was reverse transcribed and Taqman PCR was performed using 
specific Taqman probes from Roche Applied Science for Id1 (Assay ID: 104631), Smad6 (Assay ID: 
104698) or Grem1 (Assay ID: 105548). Levels of ALK receptor expression were measured in HK-2 
and HEK293 cells using Roche Taqman probes for ACVR1 (ALK 2) (Assay Id: 104525), BMPR1A 
(ALK 3) (Assay Id: 104581) and BMPR1B (ALK 6) (Assay Id: 104584). All analysis was carried out 
using the ΔΔ comparative threshold (Ct) method and normalized to an average of 18S (Assay ID: 
104092) and β-actin (Assay ID: 101125) levels. Real-time PCR was carried out on a Roche 
LightCycler 480. 
 
Statistical analysis 
All experiments were carried out a minimum of three times in duplicate, and statistically significant 
differences were detected using Student’s unpaired t-test or one-way ANOVA with Bonferroni's 
Multiple Comparison Test using GraphPad Prism. P-values <0.05 were considered significant. 
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Results 
Analysis of commercially available recombinant Grem1 and BMPs 
We first assessed the fidelity of commercial sources of recombinant Grem1 and BMPs, which are 
widely used in the field. Thus, recombinant human (rh) Grem1 and BMP-2, -4, -6 and -7 samples (all 
from R&D Systems) were prepared and subjected to 10 % SDS-PAGE in the absence of reducing 
agents and boiling (i.e. non-reducing SDS-PAGE). Protein bands were visualised by both Coomassie 
Violet staining (Fig. 1a) or Western blotting (Fig. 1b-f). Table 1 summarises the predicted molecular 
weights of the recombinant proteins versus those detected by SDS-PAGE under reducing and non-
reducing conditions.   
Two predominant bands for rhGrem1 were detected. One had a gel mobility consistent with a mass of  
25-27 kDa, close to the expected mass for a Grem1 monomer (~21 kDa), whereas the other had a mass 
of ~14 kDa. Since both species reacted strongly with antibodies specific to rhGrem1, we attributed the 
lower mass species to a Grem1 breakdown product. This lower mass species could also be a 
glycosylated Grem1 variant with an idiosynchratic gel mobility.  Notably, full length rhGrem1 was 
present at significantly higher abundance than the minor breakdown product. 
We next used size exclusion chromatography in conjunction with multi angle light scattering (SEC-
MALS) to further analyse rhGrem1. SEC-MALS is a powerful tool for directly measuring the mass, 
purity and concentration of biomolecules in solution.  Using this approach, we observed just two 
species eluting from the high resolution SEC column, with relative elution volumes of ~11.9 ml and 
~12.3 ml, with relative abundances of ~10% and ~90%, respectively, based on the integrated UV peak 
areas (Fig. 2c).  The elution profile is consistent with the results obtained using SDS-PAGE and 
Western blotting, with the most abundant species (native monomeric rGrem1) eluting later from the 
SEC column than the breakdown product/glycosylated rhGrem1 (presumably due to it being either 
unfolded or non-globular).  Unfortunately, the low molecular weight of rhGrem1 combined with the 
low protein concentrations  available meant that rGrem1 did not scatter light sufficient to determine its 
molar mass using MALS. Non-reducing SDS-PAGE and Western blotting showed that monomeric 
forms of BMP-2 and BMP-7 were the most abundant in commercial, recombinant sources (Fig. 1a, c, 
e). In contrast, higher order oligomers were observed for BMP-4 and BMP-6, although these were also 
significantly less abundant than the monomeric forms (Fig. 1d, f).  Most BMPs examined, however, 
yielded only a single species when examined using silver stained, reducing SDS-PAGE (Suppl. Fig. 
1).  This supports the view that the complexity observed on non-reducing SDS-PAGE is likely to be 
associated with oligomeric forms of BMPs refractory to denaturation (in non-reducing SDS-PAGE), 
as opposed to higher molecular weight contaminants or unprocessed BMP species.  The exception to 
this was BMP-6, which did not silver stain in our experiments, despite staining with Coomassie Blue 
(Fig. 1a, Suppl. Fig. 1a).   
SEC-MALS analysis showed that rhBMP-2 yielded only a single, symmetrical elution peak in PBS 
buffer (Fig. 2d). These results were consistent with rhBMP-2 being homogeneous, in agreement with 
the results obtained using SDS-PAGE and Western blotting.  As per rhGrem1, the protein 
concentrations used were too low to obtain a molar mass for BMP-2 using SEC-MALS.  BMP-4, 
BMP-6 and BMP-7 reproducibly failed to elute from SEC columns, precluding any objective 
assessment of their solution oligomeric state (data not shown).   
Recombinant Gremlin1 binds BMPs with different affinities 
Real-time surface plasmon resonance (SPR) was used to characterise the binding of recombinant 
human BMPs to rhGrem1. Initially, rhGrem1 was attached as “bait” to BIAcore Xantec sensorchips 
using amine-reactive coupling, and a series of rhBMPs were then used as analytes to probe for binding 
events. However, little or no BMP binding was detected, suggesting that the coupling of rhGrem1 to 
the BIAcore surface impinged on the binding interface required for BMP binding (data not shown). 
Thus, the reverse approach was then implemented and BMP-2, 4, 6, 7 were individually coupled to 
individual flow cells on the BIAcore sensor chip surface.  This approach had merit for two reasons: (i) 
to keep rGrem1 active (which is not the case when it was coupled to an SPR chip, see above); (ii) all 
BMPs will see the same rhGrem1 preparation, including the 10 % low abundance Grem1 species 
observed by SEC-MALS and Western blot discussed above (Fig. 1b). 
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Increasing concentrations of rhGrem1 (ranging from 10 nM-3 μM) were injected onto the SPR chip 
and the relative binding in response units (RU) was measured for each immobilised BMP. This 
approach gave high quality data, with excellent signal to noise ratios and yielded a set of concentration 
dependent binding kinetics (BMP-7 shown as example, Fig. 2). At the lower Grem1 concentrations 
examined (10-300 nM), there was clear evidence for association kinetics that typically report on ligand 
binding, and from which on-rates (kON) are determined. Conversely, no convincing dissociation phases 
were observed after rhGrem1 injections (10-300 nM) were ceased. This was problematic as it is these 
dissociation phases that are typically used to determine off-rates, and ultimately Kd values.  This 
phenomenon could be due to very tight binding between BMPs and rhGrem1, or irreversible, non-
specific binding of rhGrem1 to the SPR chip surface (i.e. in the absence of immobilised BMPs).  
However, no irreversible binding was observed in ‘empty’ reference channels (i.e. no immobilised 
BMPs were present). Clear dissociation phases were evident, however, for each BMP when higher 
concentrations of rhGrem1 (≥ 1 M) were injected onto the SPR chip.  We believe that this additional 
phase, which was observed only at higher concentrations of rhGrem1, most likely reflects the 
reversible binding of rhGrem1 to BMPs.   
The SPR sensorgrams were analysed in two different ways: (i) fitting the association and 
dissociation kinetics to a 1:1 Langmuir analysis, which assumes a single binding site (Table 2), (ii) 
assuming a bivalent analyte, where each rhGrem1 can bind multiple BMPs (which seems possible, as 
Grem1 has been reported to be a functional dimer).  We specifically fitted only the 3 M rhGrem1 
injections (which exhibited reversible association-dissociation kinetics), although comparable Kd 
values were obtained for the 1 M rhGrem1 datasets (data not shown). For each BMP, the dissociation 
phases fitted well to the 1:1 Langmuir function (Table 2).  The association phases fitted less well, 
although well within what is normally accepted for publication quality SPR data.  Using this approach, 
the rank order of interaction affinity, from tightest binding to the weakest, was 
BMP4=BMP2>BMP6>BMP7 (Table 2).  Fitting the data to a bivalent analyte function gave excellent 
fits, and yielded a rank order of binding affinity, from tightest binding to weakest, of BMP4 >BMP2 
>BMP6>BMP7 for the tighter of the two modelled binding events (although their absolute magnitude 
varied from those calculated using the Langmuir analysis, Suppl. Table 1).  In our opinion, the weaker 
of the two binding sites modelled using the bivalent analyte analysis did not yield physically sensible 
parameters, and the high quality fits obtained was merely a consequence of employing a fitting 
procedure that had more variables than the Langmuir analyses. 
 We next employed microscale thermophoresis to try and obtain objective independent 
validation of the binding affinities for each BMP for rhGrem1. Since our SPR experiments showed 
that coupling rhGrem1 to SPR chips inactivated it, we elected to label the BMPs with a red dye (using 
amine reactive coupling, as per our SPR experiments). Using this approach, we found that we could 
successfully label BMP4 with the red dye. By contrast, it was not possible to obtain labelled BMP-2, 
BMP-6 and BMP-7, as these proteins did not elute from to the small SEC columns used to separate 
labelled proteins from unincorporated dye.  This experiment again demonstrate the challenges of 
studying BMP interactions in vitro, as similar issues occurred in our SEC-MALS studies of BMPs 
(discussed above). 
 
 High quality binding curves were obtained when labelled BMP-4 was titrated with rhGrem1 (Fig. 
2e).  The apparent Kd of this curve (≤ 50 nM) agreed fairly well with the apparent Kd determined 
using SPR and the Langmuir analysis (Kd ~28 nM).  By contrast, the Kd determined for BMP-4-
rhGrem1 disagreed with the value obtained using a bivalent analyte analysis of the SPR data (Kd ~ 0.4 
nM).  Based on this benchmarking of the SPR data, and the problems seen with irreversible binding of 
BMPs to silica and polymer based SEC columns, we believe that our SPR data were best described by 
the 1:1 Langmuir analysis, and ignoring the apparently irreversible binding seen at low rGrem1 
concentrations (10-300nM).  Irrespective of these issues, in each case (i.e. Langmuir analysis or 
bivalent analyte), the weakest binder to rhGrem1 was BMP7, with BMP2 and BMP4 having 
considerably higher affinity for rhGrem1.   
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Differential BMP-mediated pSmad1/5/8 signalling and Gremlin1 inhibition in kidney epithelial cells  
BMP binding to heterotetrameric type I/II receptor complexes leads to Smad1/5/8 phosphorylation, 
dimerization with co-Smad4, nuclear translocation and transcriptional activation [2]. To validate the 
SPR and MST protein interaction data in a cell culture system, human kidney proximal tubule 
epithelial cells (HK-2) were incubated with increasing concentrations of rhBMPs (BMP-2; 0.5 ng/ml-
10 ng/ml, (39-790 pM), BMP-4; 0.5 ng/ml-10 ng/ml, (39-780 pM) or BMP-7; 5-50 ng/ml (325 pM-
3.25 nM)). Robust Smad1/5/8 phosphorylation was seen in response to BMP-2 at 0.5 ng/ml (Fig. 3a) 
and BMP-4 at 1-2 ng/ml (Fig. 3b). In contrast, higher concentrations of BMP-7 (> 10 ng/ml) were 
required to trigger a robust pSmad1/5/8 response in these cells (Fig. 3c). BMP-2, 4 and 7 have been 
reported to utilise similar BMP receptor complexes, with signalling transmitted via BMPRII/Alk3/6 
heterotetramers for all 3 BMPs [40]. One potential difference for the reduced response to BMP-7 may 
be the ability of BMP-7 to specifically engage with Alk2 type I receptors [41, 42]. ACVR1/ALK2 and 
BMPRIA/ALK3 were the predominant isoforms detected in HK-2 (and HEK293) cells, with levels of 
ALK6 lowest in both cases (Fig. 3d). Thus, the absence of ALK2 receptors cannot explain the lower 
efficacy of BMP-7 in HK-2 cells. 
Co-incubation of BMP-2 (5 ng/ml, 395 pM) with 25 ng/ml Grem1 (1.33 nM) completely inhibited 
BMP-2 mediated Smad1/5/8 phosphorylation (Fig. 4a, b). In contrast, inhibition of BMP-4 mediated 
Smad1/5/8 phosphorylation was not detected until 100 ng/ml Grem1 (5.3 nM) was used (Fig. 4c, d). 
BMP-7 (20 ng/ml, 1.3 nM) triggered a strong increase in Smad1/5/8 phosphorylation, but this was not 
inhibited by coincubation with Grem1 up to 400 ng/ml (21.2 nM) (Fig. 4e, f). These data demonstrate 
that the potency of BMP-2 and 4 canonical signalling exceeds that of BMP-7  in HK-2 cells, and that 
rhGrem1 inhibits BMP-2>4>7 when endogenous BMP type I/II receptor activation is measured using 
pSmad1/5/8 as a readout. BMP signalling is transmitted via pSmad1/5/8 dimer formation with Smad4 
which translocates to the nucleus and is recruited to transcriptional complexes on a defined set of 
BMP-responsive promoters of genes such as Id1-3 and Smad6 [1]. We wished to confirm that 
increased pSmad1/5/8 levels in response to BMP treatment corresponded to bona fide changes in 
BMP-mediated gene expression. Incubation of HK-2 cells with BMP-2 and 4 (10 ng/ml), and BMP-7 
(20 ng/ml) induced a significant increase in Id1 and Smad6 mRNA (Fig. 5), consistent with increased 
pSmad1/5/8 phosphorylation (Fig. 4a). For BMP-2, this transcriptional response was inhibited by 
rhGrem1 in a concentration-dependent manner, with ~ 50 % inhibition seen with 25 ng/ml Grem1 
(Fig. 5a, d). Higher amounts of Grem1 were required to inhibit BMP-4 mediated gene transcription 
which was only seen with 200 ng/ml Grem1 (Fig. 5b, e). Weak inhibition of BMP-7 stimulated 
Smad6, but not Id1 was detected up to 400 ng/ml Grem1, supporting the hypothesis that the affinity of 
Grem1 for BMP-7 homodimers is lower than for BMP-2 (Fig. 5c, f). These data highlight that Grem1 
binding to BMPs prevents receptor-mediated activation of BMP gene targets, and that the rank order 
of affinity of BMP-2>4>7 is consistent with data obtained when endogenous BMP gene targets are 
quantified. 
 
Overexpression of human Gremlin1 inhibits BMP signalling in HEK293 cells 
Given the critical role of Grem1 posttranslational processing and glycosylation in its function [43], the 
ability of Grem1 expression to inhibit BMP action when expressed in mammalian cells was then 
assessed. After optimization, a protocol was developed whereby > 80 % transfection efficiency was 
routinely obtained in HEK293 cells using pcDNA3.1A containing the human Grem1 cDNA (Fig. 6). 
Gremlin expression was detected both intracellularly (Fig. 6a) and also in the cell-cell junctions and 
extracellular space (Suppl. Fig. 3). Treatment of HEK293 cells with BMP-2 increased Smad1/5 
phosphorylation (Fig. 6a, top right panels) and transfection with myc-hGrem1 abolished this 
phosphorylation (Fig. 6a, bottom right panels). A similar profile was observed when transfected cells 
were treated BMP-4 (data not shown).  These data suggest that the transfection of cells with full-
length human Grem1 leads to the production and secretion of hGrem1 from HEK293 cells, where it 
binds to the recombinant BMPs preventing receptor activation. Consistently, Grem1 protein was 
detected when the conditioned medium from Grem1-transfected cells was analysed (Fig. 6b).  
To further interrogate the relative affinity of secreted, processed human recombinant Grem1 for BMP-
2, 4 and 7, conditioned medium from hGrem1-transfected cells was added to non-transfected HEK293 
cells in the presence of rhBMP-2, 4 or 7 (Fig. 7). “Neat” conditioned medium from Grem1-transfected 
HEK293 cells completely inhibited pSmad1/5/8 phosphorylation in response to BMP-2 and 4, but not 
BMP-7 (Fig. 7, “100 %”). Serial dilution of this conditioned medium demonstrated that recovery of 
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BMP-2 mediated Smad1/5/8 phosphorylation only occurred after 3 sequential dilutions (12.5 % 
medium, Fig. 7a, b). In contrast, Smad1/5/8 phosphorylation was detected in BMP-4 stimulated cells 
when the conditioned medium was diluted 1:4 (25 %, Fig. 7a, c). Consistent with the fact that 100 % 
conditioned medium modestly inhibited BMP-7-mediated Smad1/5/8 phosphorylation, no further 
changes were seen with sequential dilution (Fig. 7a, d). Similar results were obtained when HK-2 cells 
were used in this assay (data not shown). These data demonstrate that HEK293-produced rhGrem1 can 
inhibit BMP action in a rank order of efficacy similar to that seen with commercially available 
rhGrem1 (R&D Systems), and support the rank order of BMP-2>4>7 in terms of Grem1 binding. 
 
Cell-associated  Gremlin1 does not inhibit BMP-mediated signalling responses 
As previously reported, Grem1 is a secreted protein but also exists in cell-associated forms [1, 21]. 
Grem1 has been shown to bind to heparin and heparin sulphate proteoglycans, thus modulating its 
interaction with the VEGFR2 and subsequent pro-angiogenic activity [43]. Other evidence 
demonstrated that Grem1 acts intracellularly to regulate BMP-4 activation and secretion [23]. In order 
to assess the ability of ‘cell associated’ versus ‘soluble’ Grem1 to inhibit BMP action, HK-2 cells were 
pre-treated with medium supplemented with vehicle or 25 g/ml rhGrem1 for 60 min (Fig. 8b, d, 
Grem1 pre-incubation, removal and BMP-2 addition, right panels). The Grem1 containing medium 
was removed and cells were then treated with medium containing 4 mM HCl (BMP vehicle) or 5 
ng/ml BMP-2 (Fig. 8b, d, Grem1 pre-incubation, removal and BMP-2 addition, right panels) for a 
further 60 min. Similar to previous data, treatment of HK-2 cells with 5 ng/ml BMP-2 triggered a 
robust increase in Smad1/5/8 phosphorylation that was completely inhibited by co-incubation with  25 
ng/ml Grem1 (Fig. 8a, c, BMP-2 plus Grem1, left panels). In contrast, pre-treatment of HK-2 cells 
with 25 ng/ml rhGrem1 followed by removal of the Grem1-containing medium did not inhibit BMP-2 
mediated Smad1/5/8 phosphorylation (Fig. 8b, d, Grem1 pre-incubation, removal and BMP-2 addition, 
right panels). A similar profile of inhibition was obtained when BMP-4 was used (Suppl. Fig. 4 ). 
These data suggest that ‘cell associated’ or surface bound rhGrem1 is unable to inhibit BMP- mediated 
endogenous BMP type I/II receptor activation and Smad1/5/8 phosphorylation, compared to 
extracellular rhGrem1 in solution. 
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Discussion 
In this study, we identify that BMP proteins have differing affinities for the antagonist Grem1. 
Calculation of Kd values from SPR experiments at all concentrations of rhGrem1 examined was 
somewhat confounded by what appeared to be irreversible, or ultra-tight, binding events at low 
hGrem1 concentrations (10-300 nM).  Nonetheless, when we fitted the reversible rhGrem1-binding 
phases (i.e 1 or 3 M rhGrem1) to either one-site (Fig. 2b) or bivalent analyte binding model (data not 
shown), very similar rank orders of binding affinity were observed in vitro: BMP-4 ≥ BMP-2 > BMP-
6 > BMP-7 (Table 2).  Whilst the apparent ‘stickiness’ of BMPs to SEC columns precluded robust 
SEC-MALS experiments and labelling of most BMPs for MST experiments, the one interaction that 
we could directly measure in vitro (BMP-4/rhGrem1) to independently benchmark the SPR data, had 
an apparent Kd value that agreed well with the value using the Langmuir analysis (Fig. 2e). Thus, we 
believe that the observed SPR data is a synthesis of irreversible binding (perhaps caused by the 
stickiness of BMPs) and reversible binding.   
The nature and complexity of these interactions, combined with high cost of the recombinant proteins 
used here, and their challenging properties, conspired to make in vitro biophysical experiments very 
challenging. Further work will be needed to disentangle fully the precise mechanism interaction 
stoichiometry and ‘true affinities’. Nonetheless, we feel that the good agreement between the rank 
order of BMP-rhGrem1 interaction affinities reported here, and their associated biological activities 
and potencies in cellular experiments, represent an important step forward in higher resolution 
mechanistic and functional studies. . Protein related to Dan and Cerberus (PRDC or Grem2) also 
inhibits BMP-2 action in cell culture and whole Xenopus embryos via the formation of highly stable 
non-covalent dimers [44]. KD values estimated by Langmuir equation for Grem1 binding to BMP-2 
and BMP-4 were in the same range (low nM) as those calculated for PRDC , with the same caveats in 
place regarding Grem1-BMP affinities we present here. Other authors have shown that reduction of 
PRDC (Grem2) using DTT changed its mobility on SDS-PAGE, but not its BMP inhibitory activity 
[44].  
Using HK-2 kidney epithelial cells, the ability of Grem1 to inhibit BMP-activated Smad1/5/8 
phosphorylation and downstream target gene transcription was defined (Fig. 4, 5). In contrast to the 
SPR assays where only recombinant Grem1 and BMPs were present, this system measures Grem1-
BMP competitive binding in the presence of the type I/II BMP receptors in a cell-based assay. The 
ability of BMP-7 to trigger Smad signalling in these cells was much lower than that of BMP-2 (Fig. 
3a, b versus c). Complete inhibition of BMP-2 activity was seen with a 3.35 molar excess of Grem1, 
whereas a 13.6-fold molar excess of Grem1 was required to inhibit BMP-4 (Fig. 4, 5). In contrast, no 
significant inhibition of BMP-7 was seen with a 16.3-fold molar excess of Grem1 (Fig. 4, 5). Given 
that BMP-7 can strongly activate pSmad1/5/8 in outgrowth endothelial cells in our laboratory, we do 
not think that the fidelity of the recombinant BMP-7 is an issue here. Importantly, ACVR1/ALK2 and 
BMPRIA/ALK3 receptor mRNA was detected in HK-2 cells, suggesting that the reduced response to 
BMP-7 was not due to an absence of cognate receptors.  
Transfection of HEK293 cells with myc-hGrem1 decreased BMP-2 mediated pSmad1/5 
phosphorylation (Fig. 6a). Similar profiles of inhibition were observed when conditioned medium 
from these HEK293 cells transfected was used as a source of Grem1 (Fig. 7). These data suggest that 
the relative affinity profile seen in our experiments is not dependent on the source of Grem1 used. In 
addition, the consistent results with two independent sources of rhGrem1 suggest that that myc affinity 
tag present in rhGrem1 produced from HEK293 cells does not greatly alter Grem1 function or 
availability in the conditioned medium. How does Grem1 inhibit BMP action? Our data suggests that 
binding of Grem1 to BMPs in solution is required for its inhibitory activity, as cell-bound Grem1 was 
not sufficient for inhibition of BMP action (Fig. 8). These data also suggest that rhGrem1 is not 
binding to and preventing access to the BMP receptors. Previous groups have identified that Grem1 
can interact with several cell surface receptors including VEGFR2 and heparin sulphate proteoglycans 
[43, 45]. Our data suggest that these cell surface receptor interactions do not “capture” sufficient 
Grem1 to allow significant inhibition of BMP signalling in HK-2 cells. A different model may exist in 
endothelial and other vascular cell types that express higher levels of VEGFR2. Apart from direct 
antagonism of BMP-receptor binding, Grem1 can bind BMP-4 inside C2C12 cells and inhibit BMP-4 
maturation and secretion [23]. Recent data has also demonstrated that Grem1 can accelerate the 
endocytosis of BMP-2 into HeLa cells [22]. Given the relatively short duration of Grem1-BMP 
treatment of HK-2 cells in our experiments (60 min), we suggest that the main mechanism of Grem1-
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mediated inhibition of BMP signalling in our experiments is via direct antagonism of BMP in solution, 
preventing binding to its target receptors at the plasma membrane.  
What implications do these data have for those working on the regulation of BMP signalling 
by Grem1 and other antagonists? We and others have shown that Grem1 levels increase during DN 
whereas levels of BMP-7 decrease [33, 46]. Strategies that stimulate BMP-7 signalling have been 
shown to attenuate renal fibrosis [5, 12-17], and reductions in Grem1 levels have a similar beneficial 
effect in mouse models of DN [32, 37]. In vivo reduction of Grem1 via siRNA targeting recovered 
BMP-7 levels, suggesting that elevated Grem1 may have a role in repressing BMP-7 in DN [37]. 
However, our data suggests that this is unlikely to occur via a direct interaction between Grem1 and 
BMP-7, given their low binding affinity. Small molecules such as tilerone (which induces BMP-7) and 
Thr123 (which activates the Alk3 BMP receptor) have been shown to reduce kidney fibrosis in vivo 
[47, 48]. Together with a recent report showing that an anti-Grem1 antibody can reduce fibrosis in a 
model of pulmonary artery hypertension (PAH) [49], these data illustrate that manipulation of the 
Grem1-BMP signalling axis may still be a useful therapeutic avenue for the treatment of diabetic 
kidney disease. A recent paper identified that twisted gastrulation (Twsg1) is the most abundant BMP 
antagonist expressed in cultured kidney podocytes, and could inhibit both BMP-4 and BMP-7 in these 
cells [20]. This report highlights the likely involvement of multiple BMP antagonists in the control of 
BMP action during kidney injury.  
In summary, we have demonstrated a differential level of activity of BMPs in HK-2 epithelial 
cells, and a BMP-2>4>7 rank order of Grem1 antagonist binding to these proteins. Our data provide a 
mechanistic insight into the possible molecular interactions in the diseased kidney in diabetes and 
other chronic nephropathies.  
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Table 1. Predicted vs. observed molecular weights of rhGrem1, BMP-2, BMP-4, BMP-6 and 
BMP-7. Predicted molecular weights of the recombinant proteins were obtained from product 
datasheets from R&D systems. Observed molecular weights were obtained from Coomassie staining 
or Western blotting of recombinant proteins separated by SDS-PAGE under reducing or non-reducing 
conditions.  
  
Predicted size (kDa) 
(R&D Systems)
SDS-PAGE (kDa)
(reducing)
Observed SDS-PAGE (kDa)
(non-reducing)
Grem1 19.7 25 -30 ~ 25
BMP-2 13 15-16 30
BMP-4 13 22-25 35
BMP-6 15 18 30
BMP-7 15.7 18-20 28
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1:1 Langmuir analysis 
Protein 
kON 
(M-1s-1) 
kOFF 
(s-1) 
Kd  
(M) 
BMP-2 1.0×104 3.3×10-4 32×10-9 
BMP-4 1.2×104 3.3×10-4 28×10-9 
BMP-6 6.8×103 5.1×10-4 76×10-9 
BMP-7 1.0×104 9.2×10-4 88×10-9 
 
Table 2. Binding affinities of Grem1 for recombinant BMPs.  Sensorgrams obtained for Grem1 
binding to each rhBMP were analysed using  a 1:1 Langmuir binding model analysis with 
BiaEvaluation software allowing KON, KOFF and dissociation (KD) rate constants to be calculated. Data 
shown are a mean of duplicate values. 
  
Differential Gremlin1 binding to Bone Morphogenetic Proteins 
 
18 
 
 
Protein 
kON1 
(M-1s-1) 
kOFF1 
(s-1) 
Kd1 
(M) 
kON2 
(M-1s-1) 
kOFF2 
(s-1) 
Kd2 
(M) 
BMP-2 12,050 8.9×10-5 7.4×10-9 4.0×10-4 2.7×10-2 67 
BMP-4 14,800 6.2×10-6 4.2×10-10 8.9×10-4 0.32 36 
BMP-6 20,700 2.9×10-4 1.4×10-8 6.3×10-3 0.02 4 
BMP-7 18,600 4.6×10-4 2.5×10-8 8.8×10-4 2.6×10-2 29 
 
Supplemental Table 1. Binding affinities of Grem1 for recombinant BMPs.  Sensorgrams 
obtained for Grem1 binding to each rhBMP were analysed using  a bivalent model analysis with 
BiaEvaluation software allowing KON, KOFF and dissociation (KD) rate constants for a theoretical two 
site model to be calculated. Data shown are a mean of duplicate values. 
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Figure Legends 
 
Figure 1. Detection of rhGrem1 and rhBMPs by Coomassie violet staining and Western blot. (a) 
Recombinant human (rh) Grem1, BMP-2, BMP-4, BMP-6 and BMP-7 samples were prepared at 0.5 
µg and 1.0 µg via dilution with the appropriate vehicle (PBS (Grem1) or 4mM HCl (BMPs)) and 
added to an equal volume of 2 x Laemmli buffer in the absence of 2-mercaptoethanol (1:100) and the 
absence of sample denaturation by boiling. Samples were separated on 10 % (v/v) SDS-PAGE and 
stained with Coomassie Violet to visualise the recombinant protein.  (b-f) Recombinant human (rh) 
Grem1, BMP-2, BMP-4, BMP-6 and BMP-7 samples were prepared at 100 ng and 500 ng via dilution 
with the appropriate vehicle (PBS (Grem1) or 4 mM HCl (BMPs)) and added to an equal volume of 2 
x Laemmli buffer in the absence of 2-mercaptoethanol (1:100) and the absence of sample denaturation 
by boiling. Samples were separated by 10 % (v/v) SDS-PAGE and probed via Western blotting using 
antibodies reactive to Grem1, BMP-2, BMP-4, BMP-6 or BMP-7 as indicated. 
 
Figure 2. Recombinant hGrem1 binds to recombinant hBMPs with different affinities. (a) 
Recombinant human BMP-7 was coupled to Xantec HLC 30m SPR sensorchips as described. 
Increasing concentrations of rhGrem1 (10 nM-3 μM) were injected over the surface and the relative 
binding in response units (RU) was measured. Sensorgrams were subjected to double referencing with 
subtraction of their respective control sensorgrams and blank injections.. The injection start and end 
points are indicated. Data shown are respesentative of an individual experiment performed in 
duplicate. (b) Data were subjected to a 1:1 Langmuir binding analysis using the 3 µM Grem1 
injection data over immobilised BMPs. The turquoise line indicates the SPR binding curve and the 
black line indicates the fitting of the 1:1 binding model.(c, d) Size exclusion chromatography (SEC) 
analysis of rhGrem1 and rhBMP-2.  A 5 µL aliquot of a ~50 µM rhGrem1 (c) or rhBMP-2 (d) was 
injected onto a 15 mL analytical KW-803 SEC column.  The differential refractive index (dRI) is 
plotted against elution volume (Ve, in ml).  For rhGrem1, two species were resolved with the most 
abundant species eluting at ~12.3 ml (90 % of total sample) and the remaining 10 % eluting earlier 
(Ve of ~11.9 ml. A single elution peak was observed for BMP-2, with a Ve of ~12.1 ml. (e) Titration 
of rhGrem1 into BMP-4 measured using microscale thermophoresis (MST).  Unlabelled rhGrem1 was 
titrated against fluorescently-labelled BMP-4 (see Methods).  A 1:2 dilution series was generated, 
with 1 M Grem1 as the maximal concentration measured.  The fitted MST data yielded apparent Kd 
values in the range 40-50 nM. 
 
Figure 3. Human BMPs exhibit different efficacies of Smad 1/5/8 phosphorylation in HK-2 cells.  
Human proximal tubule epithelial cells (HK-2) cells were treated with vehicle (4 mM HCl) or 
increasing concentrations of (a) rhBMP-2, (b) rhBMP-4 or (c) rhBMP-7 as indicated for 60 min. 
Twenty μg of protein lysates were separated by 10 % SDS-PAGE and probed via Western blotting 
using antibodies reactive to pSmad1/5/8 (top panel) and β-actin (lower panel). Data are plotted as 
mean +/- SEM. The results are representative of three independent experiments performed in 
duplicate. +, positive control lysate. (d) cDNA from human proximal tubule epithelial cells (HK-2) 
and human embryonic kidney cells (HEK293) was analysed via quantitative PCR using specific 
Taqman probes for ACVR1 (ALK 2), BMPR1A (ALK 3) and BMPR1B (ALK 6). 18S and β-actin 
were used as housekeeping controls. Values shown are relative gene expression (2-Ct (gene minus 
housekeeping gene average)) +/- SEM. The results are representative of three independent 
experiments performed in triplicate. Statistical significance was determined using Student’s unpaired 
t-test (two-tailed). **, p<0.01 
 
Figure 4. Differential Grem1-mediated inhibition of BMP-stimulated Smad 1/5/8 
phosphorylation.  HK-2 cells were treated with vehicle (4 mM HCl), (a) 5 ng/ml rhBMP-2, (b) 5 
ng/ml rhBMP-4 or (c) 20 ng/ml rhBMP-7 in the absence or presence of increasing concentrations of 
rhGrem1 as indicated for 60 min. Grem1 and BMP proteins were co-incubated in HK-2 complete 
medium at 37 oC for 15 min prior to adding to cells. In (e), an additional control of BMP-2 (5 ng/ml) 
and BMP-2 (5 ng/ml) plus Gremlin (100 ng/ml) was included to confirm the integrity of the rhGrem1. 
Twenty μg of protein lysates were separated by 10 % SDS-PAGE and probed via Western blotting 
using antibodies reactive to pSmad1/5/8 (top panel) and β-actin (lower panel). (b, d, f) Band 
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intensities were calculated using Image J and plotted as a ratio of pSmad1/5/8 intensity normalised to 
-actin. Data are plotted as mean +/- SEM. The results are representative of three independent 
experiments performed in duplicate. + represents the positive control lysate. 
 
Figure 5. Grem1 inhibits BMP-mediated Id1 and Smad6 gene expression with differing 
affinities. HK-2 cells were treated with vehicle (4 mM HCl), (a, d) 10 ng/ml rhBMP-2, (b, e) 10 
ng/ml rhBMP-4 or(c, f) 20 ng/ml rhBMP-7 in the absence or presence of increasing concentrations of 
rhGrem1 as indicated for 2 h. Recombinant proteins were co-incubated in HK-2 complete medium at 
37 oC for 15 min prior to adding to the cells.  RNA was extracted, cDNA generated and quantitative 
PCR was performed using specific Taqman probes for Id1 and Smad6. Relative quantification was 
obtained using the ΔΔCt method using 18S and β-actin as housekeeping controls. The vehicle was 
used as the calibrator and set to 1 for each experiment. Values are shown as a mean fold change +/- 
SEM. Statistical significance was determined using a one-way ANOVA with Bonferroni's Multiple 
Comparison Test. The results are representative of 3 independent experiments performed in triplicate. 
*, p<0.05, **, p<0.01. 
 
Figure 6. Overexpression of human Grem1 inhibits BMP stimulation of Smad1/5/8 
phosphorylation in HEK293 cells. (a) HEK293 cells were grown on glass coverslips and transfected 
with empty plasmid (pcDNA3.1) or plasmid containing full-length human Grem1 cDNA (pcDNA3.1-
hGrem1) as described in Methods. Cells were stained with anti-myc antibody and TRITC-labelled 
anti-mouse secondary to visualise myc-Grem1. PhosphoSmad1/5/8 antibody (Cell Signaling), 
followed by FITC-labelled anti-rabbit secondary was used to visualise pSmad1/5/8. DAPI was used to 
visualise cell nuclei. Scale bars represent 50 m. (b) Conditioned medium from pcDNA3.1 
transfected or pcDNA3.1-myc-hGrem1 transfected cells was harvested, concentrated by 
centrifugation and probed via SDS-PAGE and Western blotting using anti-Grem1 antibody (R&D 
Systems). +, positive control. 
 
Figure 7. Conditioned medium containing human Grem1 inhibits BMP-mediated Smad1/5/8 
phosphorylation. (a) Conditioned medium (CM) from pcDNA3.1 or pcDNA3.1-hGrem1-transfected 
cells was harvested, concentrated via centrifugation and probed using antibody reactive to Grem1 to 
confirm expression. Fresh HEK293 cells were then treated for 60 min with rhBMP-2 (upper panels), 
rhBMP-4 (middle panels) or rhBMP-7 (lower panels) in the presence of CM from pcDNA3.1 
transfected cells, or a serial dilution of CM from pcDNA3.1-rhGrem1-transfected cells (100 %, neat 
medium, 50 %, 1:2 dilution, 25 %, 1:4 dilution, 12.5 %, 1: 8 dilution, 5 %, 1:20 dilution). Cells were 
lysed with RIPA buffer and protein extracts probed using antibodies reactive to pSmad1/5/8 or -actin 
as loading control. Band intensities were calculated using Image J and plotted as a mean ratio of 
pSmad1/5/8 intensity normalised to -actin. Data are plotted as mean +/- SD for (b) BMP-2, (c) BMP-
4 or (d) BMP-7.  
 
Figure 8. Cell associated Grem1 does not inhibit BMP-2 mediated Smad1/5/8 phosphorylation. . 
(a) A control of vehicle, BMP-2 5 ng/ml and BMP-2 5 ng/ml plus Grem1 25 ng/ml, co-incubated in 
HK-2 complete medium at 37 oC for 15 min prior to adding to cells for 60 min was included as a 
comparison. (b) HK-2 cells were treated with medium containing vehicle (PBS) or 25 ng/ml Grem1 as 
indicated for 60 min. The medium was removed and replaced with medium supplemented with 
vehicle (4mM HCl) or 5 ng/ml BMP-2 as indicated for a further 60 min Twenty μg of protein lysates 
were separated by 10 % SDS-PAGE and probed via Western blotting using antibodies reactive to 
pSmad1/5/8 (top panel) and β-actin (lower panel). Densitometry analysis with ImageJ software was 
performed on scanned X-ray films, band intensities were calculated and plotted as a ratio of 
pSmad1/5/8 intensity normalised to β-actin (c,d). Data are plotted as mean +/- SEM. The results are 
representative of three independent experiments performed in duplicate. + represents the positive 
control lysate.  
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Supplemental Figure 1. Silver stain SDS-PAGE of rhGrem1 and rhBMPs. Recombinant proteins 
(approx. 50 mM) were diluted with 2 x Laemmli buffer containing 100 mM DTT and boiled for 5 
min. Samples were then loaded onto a 20 % SDS-PAGE gel which was then stained using standard 
Silver staining protocols. The migration of each protein was calculated using Pierce PageRuler Plus 
Prestained Protein Ladder. Upper blue band, 35 kDa; pink band, 25 kDa; lower blue band, 15 kDa. 
Supplemental Figure 2. rhGrem1 binds to recombinant BMPs with different affinities. (a-d) 
Recombinant human BMPs were coupled to Xantec HLC 30m SPR sensorchips as described. 
Increasing concentrations of rhGrem1 (10 nM-3 μM) were injected over the surface and the relative 
binding in response units (RU) was measured. Sensorgrams were subjected to double referencing with 
subtraction of their respective control sensorgrams and blank injections. Data shown are 
respesentative of an individual experiment performed in duplicate. (e) A calibration curve was 
constructed from rhGrem1:rhBMP-2, 4, 6, and 7 dose response sensorgrams. The response units (RU) 
for individual BMPs were plotted against Gremlin concentration (nM) to estimate binding affinity.  
Supplemental Figure 3. Overexpression of human Grem1 in HEK293 cells. (a) HEK293 cells 
were grown on glass coverslips and transfected with empty plasmid (pcDNA3.1) or plasmid 
containing full-length human Grem1 cDNA (pcDNA3.1-hGrem1) as described in Methods. Cells were 
stained with anti-myc antibody and TRITC-labelled anti-mouse secondary to visualise myc-Grem1. 
Scale bars represent 25 m. 
Supplemental Figure 4. Cell associated Grem1 does not inhibit BMP-4 mediated Smad1/5/8 
phosphorylation. (a) A control of vehicle, BMP-4 5 ng/ml and BMP42 5 ng/ml plus Grem1 200 
ng/ml, co-incubated in HK-2 complete medium at 37 oC for 15 min prior to adding to cells for 60 min 
was included as a comparison. (b) HK-2 cells were treated with medium containing vehicle (PBS) or 
200 ng/ml Grem1 as indicated for 60 min. The medium was removed and replaced with medium 
supplemented with vehicle (4mM HCl) or 5 ng/ml BMP-4 as indicated for a further 60 min. Twenty 
μg of protein lysates were separated by 10 % SDS-PAGE and probed via Western blotting using 
antibodies reactive to pSmad1/5/8 (top panel) and β-actin (lower panel). Densitometry analysis with 
ImageJ software was performed on scanned X-ray films, band intensities were calculated and plotted 
as a ratio of pSmad1/5/8 intensity normalised to β-actin (c,d). Data are plotted as mean +/- SEM. The 
results are representative of three independent experiments performed in duplicate. + represents the 
positive control lysate. 
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Abbreviations 
 
ALK – Activin receptor-like kinase 
BMP – Bone morphogenetic protein 
C2C12 – ouse myoblast cell line 
cDNA – complementary DNA 
DAPI - 4',6-Diamidino-2-Phenylindole, Dihydrochloride 
DN – diabetic nephropathy 
EDC - 1-ethyl-3-(3-dimethylaminopropyl)carbodimide 
FITC – fluorescein 
Grem1 – Gremlin1 
HCl – hydrochloric acid 
HEK293 – human embryonic kidney cells 
HeLa – humal epithelial adenocarcinoma cells 
HEPES – 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HK-2 – human kidney epithelial cells 
KCl – potassium chloride 
NaCl – sodium chloride 
NHS - N-hydroxysuccinimide 
M – molar 
MST - microscale thermophoresis 
MW – molecular weight 
PAH – Pulmonary Artery Hypertension 
PBS – phosphate buffered saline 
PRDC – Protein related to Dan and Cerberus/Gremlin2 
rh – recombinant human 
rm – recombinant mouse 
RIPA – radioimmunoprecipitation lysis buffer 
RT-PCR – real time polymerase chain reaction 
SEC-MALS - size exclusion chromatography in conjunction with multi angle light scattering 
SDS-PAGE - sodium dodecyl sulfate polyacrylamide gel electrophoresis 
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SMAD - Sma and Mad (Mothers against decapentaplegic) 
SPR – surface plasmon resonance 
STZ – streptozotocin 
siRNA – small interfering RNA 
TGF-β - transforming growth factor beta 
TRITC – Tetramethylrhodamine 
Twsg1 – Twisted gastrulation 
VEGFR2 – Vascular endothelial growth factor receptor 2 
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